Guangzhou Jiugong, an OTC drug maker, used a color additive FDA cancelled in 1976 and fell short of CGMP.
What happened
There was no inspection. FDA reviewed records the firm sent on its behalf after FDA's May 1, 2026 request for records under section 704(a)(4) of the FD&C Act, a legal tool that lets FDA demand documents instead of visiting. The review found an OTC drug label listing "CI 16185" (FD&C Red No. 2, a color additive FDA cancelled and delisted in 1976), and found that the label, the batch formulation spreadsheet and the certificate of analysis each named a different color additive. FDA's July 28 and August 5, 2026 email requests to clarify the discrepancy went unanswered.
What FDA found
An OTC drug contains FD&C Red No. 2 (CI 16185), a color additive FDA cancelled in 1976 because it could not be proven safe, which makes the drug adulterated.
21 CFR 81.30(j)(1); FD&C Act sections 501(a)(4)(A) and 721The quality unit did not properly review raw materials and formulations, so a banned color additive ended up in the product.
21 CFR 211.22The label, the batch formulation spreadsheet and the certificate of analysis each name a different color additive, so the records do not agree with each other.
21 CFR 211.22The firm did not answer FDA's July 28 and August 5, 2026 requests to explain the color additive discrepancy.
FD&C Act section 704(a)(4)The firm's manufacturing methods and controls do not meet CGMP for finished pharmaceuticals, so its drugs are adulterated.
FD&C Act section 501(a)(2)(B); 21 CFR parts 210 and 211
What FDA wants
FDA tells the firm to answer in writing within 15 business days, covering a quality unit remediation plan, a review of all formulations for proper color additives, a list of all U.S.-distributed products and customers over three years, its quality agreement with the product owner, and a plan for batches already in U.S. distribution, including customer notices and recalls or market withdrawals.
Who should pay attention
- brands and product owners that use this firm as a contract manufacturer
- U.S. importers and distributors of OTC drugs made in China
- retailers and buyers of OTC products that contain red color additives
This is a summary. Read the original letter on fda.gov.